Development of biomarker panel to predict, prevent and create treatments tailored to the persons with human papillomavirus-induced cervical precancerous lesions

IntroductionHuman papillomavirus (HPV) induce many cancer conditions and cause cervical cancer, second in frequency of malignant disease in women.The aim was to develop biomarker panel for HPV-induced cervical precancerous diseases in patients infected with herpes simplex virus (HSV).Material and methodsThe study involved 71 women with cervical precancerous diseases (mean age 26 ± 5 years) revealed by colposcopic, cytomorphological, and ultrasound signs which were assessed according to the following: first group, 44 patients infected with HPV; second group, 27 HPV-negative patients; and third group, 30 healthy patients (controls). In cervical specimen, we identified HPV DNA of different oncogenic risk types by polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) kits (JSC SPC ‘DiaprofMed’) were used for detecting antibodies to HSV1 and/or HSV2 and for determining the avidity index. The production of pro-inflammatory cytokines, interferon-γ (IFN-γ), IFN-α, TNF-α, and interleukin-1β (IL-1β), and anti-inflammatory cytokines, IL-4, IL-10, and transforming growth factor-β1 (TGF-β1), were studied by ELISA.ResultsIn HPV-induced cervix precancerous diseases, we identified low-avidity IgG antibodies to HSV serum of 20 patients; in the serum of 17 patients, we identified average-avidity antibodies, and high-avidity antibodies were found in 2 patients only. In 14 HPV-negative patients, we found low-avidity IgG antibodies to HSV; in 10 patients, medium avidity. Patients with low-avidity IgG antibodies to herpes virus showed high and medium oncogenic risk HPV types and a decrease of IFN-γ compared to patients with medium-avidity IgG antibodies. Production of IFN-γ was suppressed also in HPV-negative patients with cervical precancers, but we found low- and medium-avidity IgG antibodies to herpes virus. In patients with low-avidity antibodies, we observed increased level of IL-10. Level of IFN-α, IL-1β, IL-2, and IL-4 did not change in patients of all groups, but TGF-β1 increased.ConclusionsIn HPV-positive patients, those with low-avidity IgG antibodies to HSV had immunosuppression, confirmed by increased TGF-β1 and violation of IFN-γ production. Therefore, in pro- and anti-inflammatory cytokines and IgG antibodies to HSV, their avidity is an important diagnostic biomarker of HPV-induced precancerous cervical diseases. Low-avidity IgG antibodies may be an indication for treatment with immunomodulators and antiviral drugs.

[1]  A. Meisels,et al.  Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. , 1976, Acta cytologica.

[2]  H. Hausen HUMAN GENITAL CANCER: SYNERGISM BETWEEN TWO VIRUS INFECTIONS OR SYNERGISM BETWEEN A VIRUS INFECTION AND INITIATING EVENTS? , 1982, The Lancet.

[3]  H. zur Hausen Human genital cancer: synergism between two virus infections or synergism between a virus infection and initiating events? , 1982, Lancet.

[4]  R Reid,et al.  Genital warts and cervical cancer. IV. A colposcopic index for differentiating subclinical papillomaviral infection from cervical intraepithelial neoplasia. , 1984, American journal of obstetrics and gynecology.

[5]  S. T. Traweek,et al.  The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. , 1991, American journal of clinical pathology.

[6]  Atypical hyperplasia and other abnormalities of prostatic epithelium. , 1993, Human pathology.

[7]  C. Woodworth,et al.  Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Stern Immunity to human papillomavirus-associated cervical neoplasia. , 1996, Advances in cancer research.

[9]  Y. Hara,et al.  Effect of herpes simplex virus on the DNA of human papillomavirus 18 , 1997, Journal of medical virology.

[10]  L. Cole,et al.  Immunoassay of human chorionic gonadotropin, its free subunits, and metabolites. , 1997, Clinical chemistry.

[11]  C. Woodworth,et al.  Relationship of stable integration of herpes simplex virus‐2 BglII N subfragmentXho2 to malignant transformation of human papillomavirus‐immortalized cervical keratinocytes , 1998, International journal of cancer.

[12]  T. Kiyono,et al.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells , 1998, Nature.

[13]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[14]  L. Brinton,et al.  Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  A. Van Daele,et al.  Angiogenesis in cervical intraepithelial neoplasia and the risk of recurrence. , 1999, American journal of obstetrics and gynecology.

[16]  P. Cristoforoni,et al.  Effects of Human Papillomavirus‐Associated Cells on Human Immunodeficiency Virus Gene Expression , 2000, Obstetrics and gynecology.

[17]  Harald zur Hausen,et al.  Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis , 2000 .

[18]  E. Hawk,et al.  Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  J. McDougall,et al.  Small Tumor Virus Genomes Are Integrated near Nuclear Matrix Attachment Regions in Transformed Cells , 2001, Journal of Virology.

[20]  J. Cuzick,et al.  The effect of stopping smoking on cervical Langerhans'cells and lymphocytes , 2001, BJOG : an international journal of obstetrics and gynaecology.

[21]  Human papillomavirus-16-E7 oncoprotein enhances the expression of adhesion molecules in cervical endothelial cells but not in human umbilical vein endothelial cells. , 2001, Journal of human virology.

[22]  D. Zimonjic,et al.  Chromosome‐mediated alterations of the MYC gene in human cancer , 2002, Journal of cellular and molecular medicine.

[23]  S. Franceschi,et al.  Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. , 2002, Journal of the National Cancer Institute.

[24]  W. McCluggage,et al.  Recent advances in immunohistochemistry in gynaecological pathology , 2002, Histopathology.

[25]  M. Bryś,et al.  Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium. , 2002, Cancer letters.

[26]  A. Degener,et al.  Involvement of Herpes Simplex Virus Type 2 in Modulation of Gene Expression of Human Papillomavirus Type 18 , 2002, International journal of immunopathology and pharmacology.

[27]  J. Nelson,et al.  The endothelin axis: emerging role in cancer , 2003, Nature Reviews Cancer.

[28]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[29]  S. Vieira,et al.  Quantification of angiogenesis in cervical cancer: a comparison among three endothelial cell markers. , 2004, Gynecologic oncology.

[30]  J. M. van der Hulst,et al.  Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 , 2004, Cancer Research.

[31]  A. Malpica,et al.  Depressed Type 1 Cytokine Synthesis by Superantigen-Activated CD4+ T Cells of Women with Human Papillomavirus-Related High-Grade Squamous Intraepithelial Lesions , 2004, Clinical Diagnostic Laboratory Immunology.

[32]  N. McMillan,et al.  A novel method for screening viral interferon-resistance genes. , 2004, Journal of Interferon and Cytokine Research.

[33]  Rebecca Richards-Kortum,et al.  Fluorescent nanocrystals for use in early cervical cancer detection. , 2005, Gynecologic oncology.

[34]  B. King,et al.  p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer , 2005, Journal of Clinical Pathology.

[35]  C. Meijer,et al.  A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions , 2005, Journal of Clinical Pathology.

[36]  Xianhe Xie,et al.  Proteomic analysis of progressive factors in uterine cervical cancer , 2005, Proteomics.

[37]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[38]  A. Scaloni,et al.  Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics. , 2005, Mass spectrometry reviews.

[39]  W. Günzburg,et al.  Viruses and human breast cancer. , 2006, Future microbiology.

[40]  P. Gariglio,et al.  In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. , 2006, Viral immunology.

[41]  Jong-Sup Park,et al.  Role of proteomics in translational research in cervical cancer , 2006, Expert review of proteomics.

[42]  M. Stanley Immune responses to human papillomavirus. , 2006, Vaccine.

[43]  G. Geiss,et al.  Discovery of Novel Methylation Biomarkers in Cervical Carcinoma by Global Demethylation and Microarray Analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[44]  Y. Kuramitsu,et al.  Proteomic analysis of cancer tissues: Shedding light on carcinogenesis and possible biomarkers , 2006, Proteomics.

[45]  K. Ault Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials , 2007, The Lancet.

[46]  Peter J. F. Snijders,et al.  Cytokine Release in HR-HPV(+) Women without and with Cervical Dysplasia (CIN II and III) or Carcinoma, Compared with HR-HPV(−) Controls , 2007, Mediators of inflammation.

[47]  E. Cambruzzi,et al.  Herpes simplex virus type 2 and Chlamydia trachomatis in adenocarcinoma of the uterine cervix. , 2007, Gynecologic oncology.

[48]  Ole Gemeinhardt,et al.  Real-time sonoelastography of the cervix: tissue elasticity of the normal and abnormal cervix. , 2007, Academic radiology.

[49]  S. Franceschi,et al.  Human papillomavirus and HPV vaccines: a review. , 2007, Bulletin of the World Health Organization.

[50]  Da‐hong Wang,et al.  Biomarkers of oxidative/nitrosative stress: an approach to disease prevention. , 2007, Acta medica Okayama.

[51]  Gun-Hee Kim,et al.  Biomarkers for oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research. , 2007, Toxicology.

[52]  Mithat Gönen,et al.  Screening for cancer with PET and PET/CT: potential and limitations. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  D. Spandidos,et al.  Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. , 2007, International journal of oncology.

[54]  Y. Hiraku,et al.  Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection , 2007, Cancer science.

[55]  Ivan M. Melnik Genetic Algorithm for Solving the Problem of an Optimum Regression Model Construction as a Discrete Optimization Problem , 2008 .

[56]  J. Lesnock,et al.  Cervical cancer screening in pregnancy. , 2008, Obstetrics and gynecology clinics of North America.

[57]  S. Tsao,et al.  Transforming growth factor beta1 promotes chromosomal instability in human papillomavirus 16 E6E7-infected cervical epithelial cells. , 2008, Cancer research.

[58]  X. Van Ostade,et al.  Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples , 2009, Proteome Science.

[59]  G. Boulet,et al.  Human Papillomavirus in Cervical Cancer Screening: Important Role as Biomarker , 2008, Cancer Epidemiology Biomarkers & Prevention.

[60]  A. Gadducci,et al.  The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. , 2008, Critical reviews in oncology/hematology.

[61]  S. Goldie,et al.  The economic burden of noncervical human papillomavirus disease in the United States. , 2008, American journal of obstetrics and gynecology.

[62]  Discussion: ‘Perinatal consequences of fetal macrosomia’ by Zhang et al , 2008 .

[63]  E. Myers The economic impact of HPV vaccines: not just cervical cancer. , 2008, American journal of obstetrics and gynecology.

[64]  M. Stanley Immune responses to human papilloma viruses. , 2009, The Indian journal of medical research.

[65]  E. Korobowicz,et al.  Prevalence of Chlamydia trachomatis and herpes simplex virus 2 in cervical carcinoma associated with human papillomavirus detected in paraffin-sectioned samples. , 2009, European journal of gynaecological oncology.

[66]  A. Botezatu,et al.  TGF-beta signalling pathway factors in HPV-induced cervical lesions. , 2010, Roumanian archives of microbiology and immunology.

[67]  J. Machac,et al.  PET/CT evaluation of cervical cancer: spectrum of disease. , 2010, Radiographics : a review publication of the Radiological Society of North America, Inc.

[68]  H. Schild,et al.  Cancer predisposition in diabetics: risk factors considered for predictive diagnostics and targeted preventive measures , 2010, EPMA Journal.

[69]  J. Flammer,et al.  Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs , 2010, EPMA Journal.

[70]  N. deSouza,et al.  Evaluation of magnetic resonance diffusion and spectroscopy measurements as predictive biomarkers in stage 1 cervical cancer. , 2010, Gynecologic oncology.

[71]  Michael House,et al.  A study of the anisotropy and tension/compression behavior of human cervical tissue. , 2010, Journal of biomechanical engineering.

[72]  Ting Wang,et al.  The role of human papillomavirus infection in breast cancer , 2012, Medical Oncology.

[73]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[74]  Niva Shapira,et al.  Women's higher health risks in the obesogenic environment: a gender nutrition approach to metabolic dimorphism with predictive, preventive, and personalised medicine , 2013, EPMA Journal.

[75]  G. Anton,et al.  Investigation of Th1/Th2 cytokine profiles in patients with laryngo-pharyngeal, HPV-positive cancers , 2013, European Archives of Oto-Rhino-Laryngology.

[76]  L. Rocha-Zavaleta,et al.  Peripheral blood lymphocytes from low-grade squamous intraepithelial lesions patients recognize vaccine antigens in the presence of activated dendritic cells, and produced high levels of CD8 + IFNγ + T cells and low levels of IL-2 when induced to proliferate , 2012, Infectious Agents and Cancer.

[77]  U. Lushchyk,et al.  Predictive and preventive strategies to advance the treatments of cardiovascular and cerebrovascular diseases: the Ukrainian context , 2012, EPMA Journal.

[78]  N. Kiviat,et al.  Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. , 2012, Gynecologic oncology.

[79]  R. Rajkumar Topics on Cervical Cancer With an Advocacy for Prevention , 2012 .

[80]  Youyun Zhao,et al.  Relationship between cervical disease and infection with human papillomavirus types 16 and 18, and herpes simplex virus 1 and 2 , 2012, Journal of medical virology.

[81]  M. Serrano,et al.  New Biomarkers for Cervical Cancer – Perspectives from the IGF System , 2012 .

[82]  H. Schild,et al.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? , 2013, EPMA Journal.

[83]  A. Verma,et al.  Evaluation of diffusion-weighted imaging as a predictive marker for tumor response in patients undergoing chemoradiation for postoperative recurrences of cervical cancer. , 2012, Journal of cancer research and therapeutics.

[84]  CHOICE OF DIAGNOSTIC DECISION MAKING IN MEDICINE AND INTERVENTION MISTAKE PREDICTION USING MATHEMATICAL MODELS , 2012 .

[85]  O. Golubnitschaja,et al.  General Report & Recommendations in Predictive, Preventive and Personalised Medicine 2012: White Paper of the European Association for Predictive, Preventive and Personalised Medicine , 2012, EPMA Journal.

[86]  A. Feigl,et al.  The Global Economic Burden of Noncommunicable Diseases , 2012 .

[87]  S. Mesogitis,et al.  Three‐dimensional power Doppler ultrasound for the study of cervical cancer and precancerous lesions , 2012, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[88]  Rostyslav V Bubnov Evidence-based pain management: is the concept of integrative medicine applicable? , 2012, EPMA Journal.

[89]  Rostyslav V Bubnov,et al.  Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application , 2013, EPMA Journal.

[90]  D. Theodorescu,et al.  Secreted Protein Acidic and Rich in Cysteine (Sparc) in Cancer , 2013 .

[91]  H. Schild,et al.  ‘Suspect molecular signature’ in blood as the indicator of undiagnosed breast cancer, cancer risk and targeted prevention , 2013, EPMA Journal.

[92]  Hong-wei Wang,et al.  Increased expression of programmed death (PD)‐1 and its ligand PD‐L1 correlates with impaired cell‐mediated immunity in high‐risk human papillomavirus‐related cervical intraepithelial neoplasia , 2013, Immunology.

[93]  Rostyslav V Bubnov,et al.  Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology , 2013, EPMA Journal.

[94]  Rostyslav V Bubnov,et al.  Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age , 2013, EPMA Journal.

[95]  Wen-lin Yang,et al.  Mechanistic investigation of immunosuppression in patients with condyloma acuminata. , 2013, Molecular medicine reports.

[96]  F. De Marco Oxidative Stress and HPV Carcinogenesis , 2013, Viruses.

[97]  John O. Prior,et al.  The role of PET/CT in cervical cancer , 2013, Front. Oncol..

[98]  F. Di Domenico,et al.  Proteomics strategies to analyze HPV-transformed cells: relevance to cervical cancer , 2013, Expert review of proteomics.